Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
January 23 2023 - 9:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of January 2023
Commission File Number 001-37652
Midatech Pharma
PLC
(Translation of registrant’s name into
English)
1 Caspian Point,
Caspian Way,
Cardiff, CF10 4DQ, United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒
Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXPLANATORY NOTE
Results of General Meeting
On January 23, 2023, Midatech Pharma PLC (the
“Company”) held its General Meeting and all ordinary resolutions were carried but all other resolutions were not passed by
shareholders. As certain resolutions were inter-conditional, only Resolution 4 (general authority to allot securities) was therefore passed.
The information included under the heading
“Results of General Meeting” of this report on Form 6-K shall be deemed to be incorporated by reference into the registration
statement on Form F-3 (File No. 333-267932) of the Company (including any prospectuses forming a part of such registration statements)
and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently
filed or furnished.
Press Release
On January 23, 2023, the Company issued a press
releasing announcing the results of its General Meeting and the appointment of Quantuma Advisory Limited, a specialist business advisory
firm, to undertake contingency planning and provide advice to the Company’s board of directors on appropriate actions. A copy of
the press release is attached hereto as Exhibit 99.1.
The information in the attached Exhibit 99.1
is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated
by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise
set forth herein or as shall be expressly set forth by specific reference in such a filing.
SUBMITTED HEREWITH
Attached to the Registrant’s Form 6-K filing
for the month of January 2023 is:
Exhibit No. | Description |
| |
99.1 | Press Release, dated January 23, 2023. |
SIGNATURE
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Midatech Pharma PLC |
|
|
Date: January 23, 2023 |
By: |
/s/ Stephen Stamp |
|
|
Stephen Stamp |
|
|
Chief Executive Officer and |
|
|
Chief Financial Officer |
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From Sep 2023 to Sep 2024